These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 1633073)

  • 1. Plasma profile and haemodynamic tolerance to isosorbide-5-mononitrate in controlled-release form.
    Jähnchen E
    Br J Clin Pharmacol; 1992; 34 Suppl 1(Suppl 1):15S-17S. PubMed ID: 1633073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of isosorbide-5-mononitrate after oral administration of an extended-release mononitrate formulation versus a standard dinitrate formulation.
    Kosoglou T; Patrick JE; Cohen A; Radwanski E; Christopher D; Affrime MB
    Clin Ther; 1995; 17(2):241-51. PubMed ID: 7614524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between pharmacokinetics and hemodynamic tolerance to isosorbide-5-mononitrate.
    Wagner F; Siefert F; Trenk D; Jähnchen E
    Eur J Clin Pharmacol; 1990; 38 Suppl 1():S53-9. PubMed ID: 2354713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The plasma concentrations of isosorbide 5-mononitrate (5-ISMN) administered in an extended-release form to patients with acute myocardial infarction.
    McClennen W; Hornestam B; Jonsson UE; Held P
    Br J Clin Pharmacol; 1995 Jun; 39(6):704-8. PubMed ID: 7654494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once- versus twice-daily administration of controlled-release isosorbide-5-mononitrate 60 mg in the treatment of stable angina pectoris. A randomized, double-blind, cross-over study. The Swedish Multicentre Group.
    Nordlander R; Walter M
    Eur Heart J; 1994 Jan; 15(1):108-13. PubMed ID: 8174569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of controlled-release isosorbide-5-mononitrate in Japanese patients with stable effort angina pectoris.
    Shimada K; Sunayama S; Nakazato K; Satoh H; Kusama Y; Kawakubo K; Daida H
    Int Heart J; 2006 Sep; 47(5):695-705. PubMed ID: 17106140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isosorbide mononitrate 30% immediate-release 70% sustained-release formulation: a review. DUMQOL (DUtch Mononitrate Quality of Life) Study Group.
    Cleophas TJ; Niemeyer MG; Zwinderman AH; van der Wall EE
    Angiology; 2000 Aug; 51(8):631-8. PubMed ID: 10959515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preserved endothelial function after long-term eccentric isosorbide mononitrate despite moderate nitrate tolerance.
    Müller S; Laber U; Müllenheim J; Meyer W; Kojda G
    J Am Coll Cardiol; 2003 Jun; 41(11):1994-2000. PubMed ID: 12798571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sex-related differences in the pharmacokinetics of isosorbide-5-mononitrate (60 mg) after repeated oral administration of two different original prolonged release formulations.
    Vree TB; Dammers E; Valducci R
    Int J Clin Pharmacol Ther; 2004 Aug; 42(8):463-72. PubMed ID: 15366327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal nitrate therapy with a once-daily sustained-release formulation of isosorbide mononitrate.
    Waller DG
    J Cardiovasc Pharmacol; 1999 Aug; 34 Suppl 2():S21-7; discussion S29-31. PubMed ID: 10499557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic profile of a new controlled-release isosorbide-5-mononitrate 60 mg scored tablet (Monoket Multitab).
    Stockis A; De Bruyn S; Deroubaix X; Jeanbaptiste B; Lebacq E; Nollevaux F; Poli G; Acerbi D
    Eur J Pharm Biopharm; 2002 Jan; 53(1):49-56. PubMed ID: 11777752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Determination of isosorbide-5-mononitrate in plasma by GC-ECD and study on its pharmacokinetics in ten volunteers].
    Yang LL; Yuan YS; Zhao FL
    Yao Xue Xue Bao; 1997 Oct; 32(10):773-6. PubMed ID: 11596222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Twenty-four hour plasma profile of sustained-release isosorbide mononitrate in healthy volunteers and in patients with chronic stable angina. Two open label trials.
    Baxter T; Eadie CJ
    Br J Clin Pharmacol; 1997 Mar; 43(3):333-5. PubMed ID: 9088592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The haemodynamic and anti-ischaemic effects of a single tablet of 80 mg isosorbide dinitrate in slow-release formulation and a review of nitrate tolerance.
    Silber S; Vogler AC; Krause KH; Theisen K
    Drugs; 1987; 33 Suppl 4():69-79. PubMed ID: 3622317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absence of pre-dose rebound phenomena with once daily 5-ISMN in a controlled-release formulation.
    Olsson G; Allgén J; Amtorp O; Nyberg G; Parker JO
    Eur Heart J; 1992 Jun; 13(6):814-7. PubMed ID: 1623873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacokinetics of nitrates.
    Bogaert MG
    Cardiovasc Drugs Ther; 1994 Oct; 8(5):693-9. PubMed ID: 7873466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioavailability of isosorbide dinitrate and its two mononitrate metabolites from sustained-release formulations.
    Chasseaud LF; Doyle E; Taylor T; Darragh A; Lambe RF
    Int J Clin Pharmacol Ther Toxicol; 1983 Oct; 21(10):514-8. PubMed ID: 6642789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-ischemic and anti-anginal effects of controlled-release and conventional isosorbide-5-mononitrate in stable angina pectoris.
    Chen YH; Ding PY; Wang SP
    Zhonghua Yi Xue Za Zhi (Taipei); 1998 Oct; 61(10):577-83. PubMed ID: 9830234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of isosorbide mononitrate.
    Abshagen UW
    Am J Cardiol; 1992 Nov; 70(17):61G-66G. PubMed ID: 1449102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A sustained release formulation of isosorbide-5-mononitrate with a rapid onset of action.
    Arthur RM; Mehmel H
    Int J Clin Pract; 1999; 53(3):205-12. PubMed ID: 10665134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.